Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fremanezumab versus placebo for prevention of chronic cluster headache
NL-OMON45623Phase 3Active, not recruiting
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Dec 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fremanezumab in Cluster Headache (CH) (3 arms), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoint: Mean change from baseline in monthly average number of cluster headache attacks over weeks 0 to 12. Started Dec 2017; status: active, not recruiting.
02
Drugs
fremanezumab
03
Conditions
Cluster Headache (CH)
Beyond the preview
Go deeper on NL-OMON45623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45623.